Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bapotulimab (BAY1905254)
Bapotulimab · 1 trial · 2 indications
Maximum plasma concentration after single dose
Area under the plasma concentration curve after single dose
| Arm | Type | Description |
|---|---|---|
| Dose escalation_Monotherapy | EXPERIMENTAL | Patients with solid tumor types considered immunosensitive |
| Dose escalation_Combination therapy | EXPERIMENTAL | Patients with solid tumor types considered immunosensitive |
| Expansion HNSCC_Combination therapy | EXPERIMENTAL | Patients with head and neck squamous cell carcinoma (HNSCC) |
| Name | Type | Description |
|---|---|---|
| Bapotulimab (BAY1905254) | DRUG | Intravenous administration of escalating doses of Bapotulimab |
| Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®) | DRUG | Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab |
Main Inclusion Criteria: * Male or female patients aged ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Patients must have measurable disease (at least one unidimensional measurable lesion by Computed tomography \[CT\] or Magnetic resonance imaging \[MRI\]) p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Bapotulimab is an investigational monoclonal antibody being developed by Bayer AG for advanced solid tumors. It is a Phase 1 clinical-stage candidate studied in oncology, including head and neck squamous cell carcinoma. Bapotulimab has also been referred to as BAY1905254 in company and trial documentation.
Bapotulimab is being studied for the treatment of advanced solid tumors, including head and neck squamous cell carcinoma that has returned or is metastatic and expresses PD-L1. It is an investigational agent and has not been approved for any indication.
Bapotulimab is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the clinical program evaluating Bapotulimab in advanced solid tumors.
Bapotulimab is in Phase 1 clinical development. The single registered trial, NCT03666273, has been completed. Bapotulimab remains an investigational drug and is not FDA approved.
Bapotulimab has been evaluated in one clinical trial, NCT03666273, a Phase 1 study in advanced solid tumors and head and neck squamous cell carcinoma conducted in the United States. The trial enrolled 60 participants and is completed.
Yes, Bapotulimab is also known as BAY1905254. BAY1905254 is the Bayer compound code used for the same monoclonal antibody, and both names refer to the same investigational oncology drug.